FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
|Articles|January 16, 2015
- Vol 32 No 1
- Volume 32
- Issue 1
Talk Radio, 2 am
Author(s)Richard M. Berlin, MD
I’m driving home from the ER, not ready for sleep, eaten up by memories of my mistakes...
Advertisement
I’m driving home from the ER,
not ready for sleep, eaten up
by memories of my mistakes,
a man on the radio telling me
not to worry because I can learn
to control my mind. He says
thoughts are like puppies
we can paper-train and teach
to be obedient. He says
one day that puppy will calm down,
cuddle up, and lick my face.
But who is this guy kidding?
My mind isn’t a puppy tonight-
it’s a wild tiger,
and it’s ripping out my heart.
Articles in this issue
over 11 years ago
Does TMS Hold Promise for Generalized Anxiety Disorder?over 11 years ago
Managing Anxiety in the Medically Illover 11 years ago
Mental Health Benefits of Exercise in Childrenover 11 years ago
Gone Girl by Gillian Flynnover 11 years ago
How to Fix the Broken Mental Health System: Ten Crucial Changesover 11 years ago
In With the Old, Out With the Newover 11 years ago
The Dynamics of Psychosis: Therapeutic Implicationsover 11 years ago
A Rational Suicide?Advertisement
Related to this article
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
A remitted patient with ARFID faces panic after a crash, showing why recovery includes somatic fear, not just eating behavior.
Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
Advertisement
Advertisement